{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,13]],"date-time":"2026-11-13T22:21:07Z","timestamp":1794608467321,"version":"4.9.1"},"reference-count":61,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T00:00:00Z","timestamp":1708732800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["391217598"],"award-info":[{"award-number":["391217598"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["369799452"],"award-info":[{"award-number":["369799452"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["391217598"],"award-info":[{"award-number":["391217598"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["369799452"],"award-info":[{"award-number":["369799452"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100010661","name":"EC | Horizon 2020 Framework Programme","doi-asserted-by":"publisher","award":["101137459"],"award-info":[{"award-number":["101137459"]}],"id":[{"id":"10.13039\/100010661","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-17-CE15-0031-01"],"award-info":[{"award-number":["ANR-17-CE15-0031-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001665","name":"Agence Nationale de la Recherche","doi-asserted-by":"publisher","award":["ANR-17-CE15-0031-01"],"award-info":[{"award-number":["ANR-17-CE15-0031-01"]}],"id":[{"id":"10.13039\/501100001665","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100008426","name":"Friedrich-Baur-Stiftung","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100008426","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KI2013"],"award-info":[{"award-number":["01KI2013"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100002347","name":"Bundesministerium f\u00fcr Bildung und Forschung","doi-asserted-by":"publisher","award":["01KI2013"],"award-info":[{"award-number":["01KI2013"]}],"id":[{"id":"10.13039\/501100002347","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Commun"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>The yellow fever 17D vaccine (YF17D) is highly effective but is frequently administered to individuals with pre-existing cross-reactive immunity, potentially impacting their immune responses. Here, we investigate the impact of pre-existing flavivirus immunity induced by the tick-borne encephalitis virus (TBEV) vaccine on the response to YF17D vaccination in 250 individuals up to 28 days post-vaccination (pv) and 22 individuals sampled one-year pv. Our findings indicate that previous TBEV vaccination does not affect the early IgM-driven neutralizing response to YF17D. However, pre-vaccination sera enhance YF17D virus infection in vitro via antibody-dependent enhancement (ADE). Following YF17D vaccination, TBEV-pre-vaccinated individuals develop high amounts of cross-reactive IgG antibodies with poor neutralizing capacity. In contrast, TBEV-unvaccinated individuals elicit a non-cross-reacting neutralizing response. Using YF17D envelope protein mutants displaying different epitopes, we identify quaternary dimeric epitopes as the primary target of neutralizing antibodies. Additionally, TBEV-pre-vaccination skews the IgG response towards the pan-flavivirus fusion loop epitope (FLE), capable of mediating ADE of dengue and Zika virus infections in vitro. Together, we propose that YF17D vaccination conceals the FLE in individuals without prior flavivirus exposure but favors a cross-reactive IgG response in TBEV-pre-vaccinated recipients directed to the FLE with potential to enhance dengue virus infection.<\/jats:p>","DOI":"10.1038\/s41467-024-45806-x","type":"journal-article","created":{"date-parts":[[2024,2,24]],"date-time":"2024-02-24T05:01:54Z","timestamp":1708750914000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":46,"title":["Prior flavivirus immunity skews the yellow fever vaccine response to cross-reactive antibodies with potential to enhance dengue virus infection"],"prefix":"10.1038","volume":"15","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-2167-5432","authenticated-orcid":false,"given":"Antonio","family":"Santos-Peral","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabian","family":"Luppa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3586-6498","authenticated-orcid":false,"given":"Sebastian","family":"Goresch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elena","family":"Nikolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3590-1525","authenticated-orcid":false,"given":"Magdalena","family":"Zaucha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5153-3371","authenticated-orcid":false,"given":"Lisa","family":"Lehmann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Frank","family":"Dahlstroem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2264-4395","authenticated-orcid":false,"given":"Hadi","family":"Karimzadeh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4879-4159","authenticated-orcid":false,"given":"Julia","family":"Thorn-Seshold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0364-662X","authenticated-orcid":false,"given":"Elena","family":"Winheim","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ev-Marie","family":"Schuster","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerhard","family":"Dobler","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7642-1835","authenticated-orcid":false,"given":"Michael","family":"Hoelscher","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9011-2764","authenticated-orcid":false,"given":"Beate M.","family":"K\u00fcmmerer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stefan","family":"Endres","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9323-9472","authenticated-orcid":false,"given":"Kilian","family":"Schober","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9556-7207","authenticated-orcid":false,"given":"Anne B.","family":"Krug","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Pritsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2069-9501","authenticated-orcid":false,"given":"Giovanna","family":"Barba-Spaeth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1151-7614","authenticated-orcid":false,"given":"Simon","family":"Rothenfusser","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,2,24]]},"reference":[{"key":"45806_CR1","doi-asserted-by":"publisher","first-page":"532","DOI":"10.1038\/nrmicro2595","volume":"9","author":"N Vasilakis","year":"2011","unstructured":"Vasilakis, N., Cardosa, J., Hanley, K. A., Holmes, E. C. & Weaver, S. C. Fever from the forest: prospects for the continued emergence of sylvatic dengue virus and its impact on public health. Nat. Rev. Microbiol. 9, 532\u2013541 (2011).","journal-title":"Nat. Rev. Microbiol."},{"key":"45806_CR2","doi-asserted-by":"publisher","DOI":"10.7554\/eLife.08347","volume":"4","author":"MUG Kraemer","year":"2015","unstructured":"Kraemer, M. U. G. et al. The global distribution of the arbovirus vectors Aedes aegypti and Ae. albopictus. Jit M, editor. Elife 4, e08347 (2015).","journal-title":"Elife"},{"key":"45806_CR3","doi-asserted-by":"publisher","first-page":"500","DOI":"10.1016\/S0140-6736(08)60238-X","volume":"371","author":"EA Gould","year":"2008","unstructured":"Gould, E. A. & Solomon, T. Pathogenic flaviviruses. Lancet 371, 500\u2013509 (2008).","journal-title":"Lancet"},{"key":"45806_CR4","doi-asserted-by":"publisher","first-page":"796","DOI":"10.1038\/s41564-020-0714-0","volume":"5","author":"TC Pierson","year":"2020","unstructured":"Pierson, T. C. & Diamond, M. S. The continued threat of emerging flaviviruses. Nat. Microbiol. 5, 796\u2013812 (2020).","journal-title":"Nat. Microbiol"},{"key":"45806_CR5","doi-asserted-by":"crossref","unstructured":"Stiasny, K., Medits, I., Ro\u00dfbacher, L., Heinz, F. X. Impact of structural dynamics on biological functions of flaviviruses. FEBS J. 290, 1973\u20131985 (2022).","DOI":"10.1111\/febs.16419"},{"key":"45806_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1016\/j.jcv.2012.08.024","volume":"55","author":"FX Heinz","year":"2012","unstructured":"Heinz, F. X. & Stiasny, K. Flaviviruses and their antigenic structure. J. Clin. Virol. 55, 289\u2013295 (2012).","journal-title":"J. Clin. Virol."},{"key":"45806_CR7","doi-asserted-by":"publisher","first-page":"51","DOI":"10.1016\/j.coviro.2020.07.006","volume":"45","author":"M Sevvana","year":"2020","unstructured":"Sevvana, M. & Kuhn, R. J. Mapping the diverse structural landscape of the flavivirus antibody repertoire. Curr. Opin. Virol. 45, 51\u201364 (2020).","journal-title":"Curr. Opin. Virol."},{"key":"45806_CR8","doi-asserted-by":"publisher","first-page":"3269","DOI":"10.1038\/emboj.2009.245","volume":"28","author":"MV Cherrier","year":"2009","unstructured":"Cherrier, M. V. et al. Structural basis for the preferential recognition of immature flaviviruses by a fusion-loop antibody. EMBO J. 28, 3269\u20133276 (2009).","journal-title":"EMBO J."},{"key":"45806_CR9","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/j.chom.2010.08.007","volume":"8","author":"M Beltramello","year":"2010","unstructured":"Beltramello, M. et al. The Human Immune Response To Dengue Virus Is Dominated By Highly Cross-reactive Antibodies Endowed With Neutralizing And Enhancing Activity. Cell Host Microbe 8, 271\u2013283 (2010).","journal-title":"Cell Host Microbe"},{"key":"45806_CR10","doi-asserted-by":"publisher","first-page":"170","DOI":"10.1038\/ni.3058","volume":"16","author":"W Dejnirattisai","year":"2015","unstructured":"Dejnirattisai, W. et al. A new class of highly potent, broadly neutralizing antibodies isolated from viremic patients infected with dengue virus. Nat. Immunol. 16, 170\u2013177 (2015).","journal-title":"Nat. Immunol."},{"key":"45806_CR11","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1038\/nature18938","volume":"536","author":"G Barba-Spaeth","year":"2016","unstructured":"Barba-Spaeth, G. et al. Structural basis of potent Zika\u2013dengue virus antibody cross-neutralization. Nature 536, 48\u201353 (2016).","journal-title":"Nature"},{"key":"45806_CR12","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1038\/nature14130","volume":"520","author":"A Rouvinski","year":"2015","unstructured":"Rouvinski, A. et al. Recognition determinants of broadly neutralizing human antibodies against dengue viruses. Nature 520, 109\u2013113 (2015).","journal-title":"Nature"},{"key":"45806_CR13","doi-asserted-by":"publisher","first-page":"206","DOI":"10.15252\/embr.201745302","volume":"19","author":"FA Rey","year":"2018","unstructured":"Rey, F. A., Stiasny, K., Vaney, M. C., Dellarole, M. & Heinz, F. X. The bright and the dark side of human antibody responses to flaviviruses: lessons for vaccine design. EMBO Rep. 19, 206\u2013224 (2018).","journal-title":"EMBO Rep."},{"key":"45806_CR14","doi-asserted-by":"publisher","first-page":"11800","DOI":"10.1128\/JVI.05237-11","volume":"85","author":"I Rodenhuis-Zybert","year":"2011","unstructured":"Rodenhuis-Zybert, I. et al. A fusion-loop antibody enhances the infectious properties of immature Flavivirus particles. J. Virol. 85, 11800\u201311808 (2011).","journal-title":"J. Virol."},{"key":"45806_CR15","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1126\/science.aan6836","volume":"358","author":"LC Katzelnick","year":"2017","unstructured":"Katzelnick, L. C. et al. Antibody-dependent enhancement of severe dengue disease in humans. Science 358, 929\u2013932 (2017).","journal-title":"Science"},{"key":"45806_CR16","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1126\/science.1185181","volume":"328","author":"W Dejnirattisai","year":"2010","unstructured":"Dejnirattisai, W. et al. Cross-reacting antibodies enhance dengue virus infection in humans. Science 328, 745\u2013748 (2010).","journal-title":"Science"},{"key":"45806_CR17","doi-asserted-by":"publisher","first-page":"1102","DOI":"10.1038\/ni.3515","volume":"17","author":"W Dejnirattisai","year":"2016","unstructured":"Dejnirattisai, W. et al. Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat. Immunol. 17, 1102\u20131108 (2016).","journal-title":"Nat. Immunol."},{"key":"45806_CR18","doi-asserted-by":"publisher","first-page":"e1311","DOI":"10.1371\/journal.pntd.0001311","volume":"5","author":"KB Anderson","year":"2011","unstructured":"Anderson, K. B. et al. Preexisting Japanese Encephalitis virus neutralizing antibodies and increased symptomatic dengue illness in a school-based cohort in Thailand. PLoS Negl. Trop. Dis. 5, e1311 (2011).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"45806_CR19","doi-asserted-by":"publisher","first-page":"e25","DOI":"10.1016\/S1473-3099(17)30360-2","volume":"18","author":"A Singanayagam","year":"2018","unstructured":"Singanayagam, A., Zambon, M., Lalvani, A. & Barclay, W. Urgent challenges in implementing live attenuated influenza vaccine. Lancet Infect. Dis. 18, e25\u2013e32 (2018).","journal-title":"Lancet Infect. Dis."},{"key":"45806_CR20","doi-asserted-by":"publisher","first-page":"16164","DOI":"10.1038\/nmicrobiol.2016.164","volume":"1","author":"KR Chan","year":"2016","unstructured":"Chan, K. R. et al. Cross-reactive antibodies enhance live attenuated virus infection for increased immunogenicity. Nat. Microbiol 1, 16164 (2016).","journal-title":"Nat. Microbiol"},{"key":"45806_CR21","doi-asserted-by":"crossref","unstructured":"Mok, D. Z. L., Chan, K. R. The effects of pre-existing antibodies on live-attenuated viral vaccines. Viruses 12, 520 (2020).","DOI":"10.3390\/v12050520"},{"key":"45806_CR22","doi-asserted-by":"publisher","first-page":"12","DOI":"10.1016\/j.jaut.2017.04.008","volume":"83","author":"A Vatti","year":"2017","unstructured":"Vatti, A. et al. Original antigenic sin: A comprehensive review. J. Autoimmun. 83, 12\u201321 (2017).","journal-title":"J. Autoimmun."},{"key":"45806_CR23","first-page":"895","volume":"59","author":"JD Poland","year":"1981","unstructured":"Poland, J. D., Calisher, C. H., Monath, T. P., Downs, W. G. & Murphy, K. Persistence of neutralizing antibody 30-35 years after immunization with 17D yellow fever vaccine. Bull. World Health Organ 59, 895\u2013900 (1981).","journal-title":"Bull. World Health Organ"},{"key":"45806_CR24","doi-asserted-by":"crossref","unstructured":"Kling, K. et al. Duration of protection after vaccination against yellow fever - systematic review and meta-analysis. Clin. Infect. Dis. 75, 2266\u20132227 (2022).","DOI":"10.1093\/cid\/ciac580"},{"key":"45806_CR25","doi-asserted-by":"publisher","first-page":"262","DOI":"10.1016\/j.virol.2005.04.031","volume":"337","author":"S Daffis","year":"2005","unstructured":"Daffis, S. et al. Antibody responses against wild-type yellow fever virus and the 17D vaccine strain: Characterization with human monoclonal antibody fragments and neutralization escape variants. Virology 337, 262\u2013272 (2005).","journal-title":"Virology"},{"key":"45806_CR26","doi-asserted-by":"publisher","DOI":"10.1128\/mbio.00512-22","volume":"13","author":"MP Doyle","year":"2022","unstructured":"Doyle, M. P. et al. Isolation of a potently neutralizing and protective human monoclonal antibody targeting yellow fever virus. mBio 13, e00512-22 (2022).","journal-title":"mBio"},{"key":"45806_CR27","doi-asserted-by":"publisher","first-page":"438","DOI":"10.1016\/j.celrep.2018.12.065","volume":"26","author":"X Lu","year":"2019","unstructured":"Lu, X. et al. Double Lock of a Human Neutralizing and Protective Monoclonal Antibody Targeting the Yellow Fever Virus Envelope. Cell Rep. 26, 438\u2013446.e5 (2019).","journal-title":"Cell Rep."},{"key":"45806_CR28","first-page":"100323","volume":"3","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. A neutralizing-protective supersite of human monoclonal antibodies for yellow fever virus. Innovation 3, 100323 (2022).","journal-title":"Innovation"},{"key":"45806_CR29","doi-asserted-by":"crossref","unstructured":"Wec, A. Z. et al. Longitudinal dynamics of the human B cell response to the yellow fever 17D vaccine. Proc. Natl Acad. Sci. 117, 6675\u20136685 (2020).","DOI":"10.1073\/pnas.1921388117"},{"key":"45806_CR30","doi-asserted-by":"publisher","first-page":"e1003458","DOI":"10.1371\/journal.ppat.1003458","volume":"9","author":"O Vratskikh","year":"2013","unstructured":"Vratskikh, O. et al. Dissection of antibody specificities induced by yellow fever vaccination. PLoS Pathog. 9, e1003458 (2013).","journal-title":"PLoS Pathog."},{"key":"45806_CR31","doi-asserted-by":"publisher","DOI":"10.1038\/s41541-019-0133-5","volume":"4","author":"V Bradt","year":"2019","unstructured":"Bradt, V. et al. Pre-existing yellow fever immunity impairs and modulates the antibody response to tick-borne encephalitis vaccination. NPJ Vaccines 4, 38 (2019).","journal-title":"NPJ Vaccines"},{"key":"45806_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1371\/journal.pntd.0008034","volume":"14","author":"S Malafa","year":"2020","unstructured":"Malafa, S. et al. Impact of flavivirus vaccine-induced immunity on primary Zika virus antibody response in humans. PLoS Negl. Trop. Dis. 14, 1\u201327 (2020).","journal-title":"PLoS Negl. Trop. Dis."},{"key":"45806_CR33","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1002\/jmv.1890170106","volume":"17","author":"M Kayser","year":"1985","unstructured":"Kayser, M. et al. Human antibody response to immunization with 17D yellow fever and inactivated TBE vaccine. J. Med Virol. 17, 35\u201345 (1985).","journal-title":"J. Med Virol."},{"key":"45806_CR34","doi-asserted-by":"publisher","first-page":"673 LP","DOI":"10.4049\/jimmunol.98.4.673","volume":"98","author":"WL Pond","year":"1967","unstructured":"Pond, W. L., Ehrenkranz, N. J., Danauskas, J. X. & Carter, M. J. Heterotypic serologic responses after yellow fever vaccination; detection of persons with past St. Louis Encephalitis or Dengue. J. Immunol. 98, 673 LP\u2013673682 (1967).","journal-title":"J. Immunol."},{"key":"45806_CR35","doi-asserted-by":"publisher","first-page":"613","DOI":"10.1016\/j.biologicals.2010.07.004","volume":"38","author":"JH Ch\u00e1vez","year":"2010","unstructured":"Ch\u00e1vez, J. H., Silva, J. R., Amarilla, A. A. & Moraes Figueiredo, L. T. Domain III peptides from flavivirus envelope protein are useful antigens for serologic diagnosis and targets for immunization. Biologicals 38, 613\u2013618 (2010).","journal-title":"Biologicals"},{"key":"45806_CR36","doi-asserted-by":"publisher","DOI":"10.1038\/srep36288","volume":"6","author":"C Li","year":"2016","unstructured":"Li, C. et al. Identification of a new broadly cross-reactive epitope within Domain III of the Duck Tembusu Virus E Protein. Sci. Rep. 6, 36288 (2016).","journal-title":"Sci. Rep."},{"key":"45806_CR37","doi-asserted-by":"publisher","first-page":"2191","DOI":"10.1099\/vir.0.055178-0","volume":"94","author":"XQ Li","year":"2013","unstructured":"Li, X. Q. et al. Dengue virus envelope domain III immunization elicits predominantly cross-reactive, poorly neutralizing antibodies localized to the AB loop: implications for dengue vaccine design. J. Gen. Virol. 94, 2191\u20132201 (2013).","journal-title":"J. Gen. Virol."},{"key":"45806_CR38","doi-asserted-by":"publisher","first-page":"4101","DOI":"10.1128\/JCM.42.9.4101-4110.2004","volume":"42","author":"M Holbrook","year":"2004","unstructured":"Holbrook, M., Shope, R. & Barrett, A. D. Use of Recombinant E Protein Domain III-Based Enzyme-Linked Immunosorbent Assays for Differentiation of Tick-Borne Encephalitis Serocomplex Flaviviruses from Mosquito-Borne Flaviviruses. J. Clin. Microbiol 42, 4101\u20134110 (2004).","journal-title":"J. Clin. Microbiol"},{"key":"45806_CR39","doi-asserted-by":"crossref","unstructured":"Crampon, E. et al. New insight into flavivirus maturation from structure\/function studies of the yellow fever virus envelope protein complex. mBio. 14, e00706-23 (2023).","DOI":"10.1128\/mbio.00706-23"},{"key":"45806_CR40","doi-asserted-by":"crossref","unstructured":"Rouvinski, A. et al. Covalently linked dengue virus envelope glycoprotein dimers reduce exposure of the immunodominant fusion loop epitope. Nat. Commun. 8, 15411 (2017).","DOI":"10.1038\/ncomms15411"},{"key":"45806_CR41","doi-asserted-by":"publisher","first-page":"1291","DOI":"10.1038\/s41590-019-0477-z","volume":"20","author":"JL Slon-Campos","year":"2019","unstructured":"Slon-Campos, J. L. et al. A protective Zika virus E-dimer-based subunit vaccine engineered to abrogate antibody-dependent enhancement of dengue infection. Nat. Immunol. 20, 1291\u20131298 (2019).","journal-title":"Nat. Immunol."},{"key":"45806_CR42","doi-asserted-by":"publisher","first-page":"346","DOI":"10.3390\/v14020346","volume":"14","author":"AC L\u00fccke","year":"2022","unstructured":"L\u00fccke, A. C. et al. High-throughput platform for detection of neutralizing antibodies using flavivirus reporter replicon particles. Viruses 14, 346 (2022).","journal-title":"Viruses"},{"key":"45806_CR43","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cell.2022.11.032","volume":"186","author":"T H\u00e4ggl\u00f6f","year":"2023","unstructured":"H\u00e4ggl\u00f6f, T. et al. Continuous germinal center invasion contributes to the diversity of the immune response. Cell 186, 147\u2013161.e15 (2023).","journal-title":"Cell"},{"key":"45806_CR44","doi-asserted-by":"crossref","unstructured":"Singh, T. et al. A Zika virus-specific IgM elicited in pregnancy exhibits ultrapotent neutralization. Cell. 185, 4826\u20134840 (2022).","DOI":"10.1016\/j.cell.2022.10.023"},{"key":"45806_CR45","doi-asserted-by":"publisher","first-page":"13845","DOI":"10.1128\/JVI.02086-14","volume":"88","author":"J Jarmer","year":"2014","unstructured":"Jarmer, J. et al. Variation of the specificity of the human antibody responses after Tick-borne Encephalitis virus infection and vaccination. J. Virol. 88, 13845\u201313857 (2014).","journal-title":"J. Virol."},{"key":"45806_CR46","doi-asserted-by":"publisher","first-page":"1078","DOI":"10.1016\/j.immuni.2020.09.001","volume":"53","author":"R Wong","year":"2020","unstructured":"Wong, R. et al. Affinity-restricted memory B cells dominate recall responses to heterologous flaviviruses. Immunity 53, 1078\u20131094.e7 (2020).","journal-title":"Immunity"},{"key":"45806_CR47","doi-asserted-by":"publisher","first-page":"735","DOI":"10.1038\/s41586-022-05609-w","volume":"613","author":"D Schaefer-Babajew","year":"2023","unstructured":"Schaefer-Babajew, D. et al. Antibody feedback regulates immune memory after SARS-CoV-2 mRNA vaccination. Nature 613, 735\u2013742 (2023).","journal-title":"Nature"},{"key":"45806_CR48","doi-asserted-by":"publisher","first-page":"6631","DOI":"10.1128\/JVI.00316-08","volume":"82","author":"L Chih-Yun","year":"2008","unstructured":"Chih-Yun, L. et al. Antibodies to envelope glycoprotein of dengue virus during the natural course of infection are predominantly cross-reactive and recognize epitopes containing highly conserved residues at the fusion loop of Domain II. J. Virol. 82, 6631\u20136643 (2008).","journal-title":"J. Virol."},{"key":"45806_CR49","doi-asserted-by":"publisher","first-page":"25","DOI":"10.1016\/j.tmaid.2019.05.002","volume":"30","author":"MJ Luppe","year":"2019","unstructured":"Luppe, M. J. et al. Yellow fever (YF) vaccination does not increase dengue severity: A retrospective study based on 11,448 dengue notifications in a YF and dengue endemic region. Travel. Med. Infect. Dis. 30, 25\u201331 (2019).","journal-title":"Travel. Med. Infect. Dis."},{"key":"45806_CR50","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1873-8","volume":"16","author":"Y Saito","year":"2016","unstructured":"Saito, Y. et al. Japanese encephalitis vaccine-facilitated dengue virus infection-enhancement antibody in adults. BMC Infect. Dis. 16, 578 (2016).","journal-title":"BMC Infect. Dis."},{"key":"45806_CR51","doi-asserted-by":"crossref","unstructured":"Santonja, I. et al. Tick-Borne Encephalitis in vaccinated patients: a retrospective case-control study and analysis of vaccination field effectiveness in Austria from 2000 to 2018. J. Infect. Dis. 227, 512\u2013521 (2023).","DOI":"10.1093\/infdis\/jiac075"},{"key":"45806_CR52","doi-asserted-by":"publisher","first-page":"1123","DOI":"10.1126\/science.abb6143","volume":"369","author":"LC Katzelnick","year":"2020","unstructured":"Katzelnick, L. C. et al. Zika virus infection enhances future risk of severe dengue disease. Science 369, 1123\u20131128 (2020).","journal-title":"Science"},{"key":"45806_CR53","doi-asserted-by":"publisher","first-page":"2001937","DOI":"10.2807\/1560-7917.ES.2022.27.2.2001937","volume":"27","author":"CM Gossner","year":"2022","unstructured":"Gossner, C. M. et al. Dengue virus infections among European travellers, 2015 to 2019. Eur. Surveill. 27, 2001937 (2022).","journal-title":"Eur. Surveill."},{"key":"45806_CR54","doi-asserted-by":"publisher","first-page":"482","DOI":"10.2144\/03353bm08","volume":"35","author":"T Iwaki","year":"2003","unstructured":"Iwaki, T., Figuera, M., Ploplis, V. A. & Castellino, F. J. Rapid selection of Drosophila S2 cells with the puromycin resistance gene. Biotechniques 35, 482\u2013486 (2003).","journal-title":"Biotechniques"},{"key":"45806_CR55","doi-asserted-by":"crossref","unstructured":"Tan, J. L., Lok, S. M. Dengue Virus Purification and Sample Preparation for Cryo-Electron Microscopy BT - Dengue: Methods and Protocols. In: Padmanabhan R., Vasudevan S. G., editors. New York, NY: Springer New York. p. 41\u201352; 2014","DOI":"10.1007\/978-1-4939-0348-1_4"},{"key":"45806_CR56","doi-asserted-by":"publisher","first-page":"e0262149","DOI":"10.1371\/journal.pone.0262149","volume":"17","author":"MK Scheck","year":"2022","unstructured":"Scheck, M. K. et al. FluoRNT: A robust, efficient assay for the detection of neutralising antibodies against yellow fever virus 17D. PLoS One 17, e0262149 (2022).","journal-title":"PLoS One"},{"key":"45806_CR57","volume":"4","author":"A Baer","year":"2014","unstructured":"Baer, A. & Kehn-Hall, K. Viral concentration determination through plaque assays: using traditional and novel overlay systems. J. Vis. Exp. 4, e52065 (2014).","journal-title":"J. Vis. Exp."},{"key":"45806_CR58","doi-asserted-by":"publisher","first-page":"177","DOI":"10.1128\/CVI.00078-07","volume":"15","author":"N Matthias","year":"2008","unstructured":"Matthias, N., Oliver, K., Christian, H. & Karen, S. Evaluation of an Indirect Immunofluorescence Assay for Detection of Immunoglobulin M (IgM) and IgG Antibodies against Yellow Fever Virus. Clin. Vaccin. Immunol. 15, 177\u2013181 (2008).","journal-title":"Clin. Vaccin. Immunol."},{"key":"45806_CR59","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1016\/j.jcv.2012.02.016","volume":"54","author":"K Stiasny","year":"2012","unstructured":"Stiasny, K. et al. Quantitative determination of IgM antibodies reduces the pitfalls in the serodiagnosis of tick-borne encephalitis. J. Clin. Virol. 54, 115\u2013120 (2012).","journal-title":"J. Clin. Virol."},{"key":"45806_CR60","first-page":"448","volume":"255","author":"H Hofmann","year":"1983","unstructured":"Hofmann, H., Heinz, F. X. & Dippe, H. ELISA for IgM and IgG antibodies against tick-borne encephalitis virus: Quantification and standardization of results. Zentralbl. Bakteriol. Mikrobiol. Hyg. A Med. 255, 448\u2013455 (1983).","journal-title":"Zentralbl. Bakteriol. Mikrobiol. Hyg. A Med."},{"key":"45806_CR61","doi-asserted-by":"publisher","first-page":"582","DOI":"10.1038\/nprot.2009.28","volume":"4","author":"BA Tannous","year":"2009","unstructured":"Tannous, B. A. Gaussia luciferase reporter assay for monitoring biological processes in culture and in vivo. Nat. Protoc. 4, 582\u2013591 (2009).","journal-title":"Nat. Protoc."}],"container-title":["Nature Communications"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45806-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45806-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,27]],"date-time":"2024-02-27T09:03:08Z","timestamp":1709024588000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41467-024-45806-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,2,24]]},"references-count":61,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["45806"],"URL":"https:\/\/doi.org\/10.1038\/s41467-024-45806-x","relation":{},"ISSN":["2041-1723"],"issn-type":[{"value":"2041-1723","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,2,24]]},"assertion":[{"value":"3 July 2023","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 February 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The authors declare no competing interests. This work was supported by FlavImmunity a combined grant of the German Research foundation (DFG) project number 391217598 to SR and ABK and the French National Research Agency (ANR) project number ANR-17-CE15-0031-01 to GBS; by DFG TRR237 grant project number 369799452 to SR and ABK (TRR237 TPB14) and BMK (TRR237 TPA04); by Yellow4Flavi a horizon Europe grant project number 101137459 funded by the European Union to SR, AK GBS, KS; by grants of the iMed consortium of the German Helmholtz Societies to SR; by the Einheit f\u00fcr Klinische Pharmakologie (EKLIP), Helmholtz Zentrum M\u00fcnchen, Neuherberg, Germany to SR and SE; KS and EMS are supported by the BMBF, project 01KI2013; a Stipend (TI 07.003) by the German Center for Infection Research (DZIF) to FL; grants by the Friedrich Baur Foundation (FBS) to JTS, HK and MP; a Metiphys fellowship of the Medical Faculty of the LMU Munich to MP; by the F\u00f6FoLe Program of the Medical Faculty of the LMU Munich to SG, EN, LL, FL, the international doctoral program \u201ciTarget: Immunotargeting of cancer\u201d funded by the Elite Network of Bavaria to ASP, MZ, SG, LL, EN. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1696"}}